DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96,456 | +48.7% | 4,677 | +112.7% | 0.00% | – |
| Q2 2023 | $64,871 | +21.5% | 2,199 | -5.1% | 0.00% | – |
| Q1 2023 | $53,388 | -13.3% | 2,318 | +4.4% | 0.00% | – |
| Q4 2022 | $61,557 | -29.2% | 2,220 | -21.6% | 0.00% | – |
| Q3 2022 | $87,000 | +31.8% | 2,830 | +25.0% | 0.00% | – |
| Q2 2022 | $66,000 | -12.0% | 2,264 | -2.3% | 0.00% | – |
| Q1 2022 | $75,000 | -21.1% | 2,317 | +10.2% | 0.00% | – |
| Q4 2021 | $95,000 | +18.8% | 2,103 | +34.7% | 0.00% | – |
| Q3 2021 | $80,000 | +48.1% | 1,561 | +123.6% | 0.00% | – |
| Q2 2021 | $54,000 | +12.5% | 698 | -16.2% | 0.00% | – |
| Q1 2021 | $48,000 | -62.5% | 833 | -45.3% | 0.00% | – |
| Q4 2020 | $128,000 | +374.1% | 1,522 | +102.9% | 0.00% | – |
| Q3 2020 | $27,000 | +17.4% | 750 | -21.1% | 0.00% | – |
| Q2 2020 | $23,000 | +9.5% | 950 | -20.4% | 0.00% | – |
| Q1 2020 | $21,000 | – | 1,193 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |